SCHEMBL324798

SCHEMBL324798

Cc1ccccc1COC(=O)N1C=Cc2ccccc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.40
ALDH1A1 P00352 4/20 0.37
MAOB P27338 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
ADORA2A P29274 1/20 0.37
F13A1 P00488 1/20 0.37
TGM2 P21980 1/20 0.37
TGM1 P22735 1/20 0.37
HDAC3 O15379 1/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
S1PR1 P21453 1/20 0.34
S1PR5 Q9H228 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322945 0.92 ALDH1A1 (0.35) GRIN2BALDH1A1KDM4EMAPTHDAC3
SCHEMBL324992 0.88 NPSR1 (0.37) GRIN2BHDAC3MEN1KMT2ANPC1
SCHEMBL324429 0.88 HDAC3 (0.36) ALDH1A1KDM4EMAPTHDAC3MEN1
SCHEMBL323574 0.86 GRIN2B (0.41) GRIN2BALDH1A1KDM4EMAPTGAA
SCHEMBL325479 0.85 RECQL (0.41) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL15056964 0.85 HDAC3 (0.41) GRIN2BALDH1A1KDM4EMAPTHDAC3
SCHEMBL29493251 0.85 HDAC3 (0.41) GRIN2BALDH1A1KDM4EMAPTHDAC3
SCHEMBL322852 0.85 MMP1 (0.39) ALDH1A1KDM4EMAPTHDAC3KMT2A
SCHEMBL324263 0.85 L3MBTL1 (0.40) ALDH1A1MAOBMAPTF13A1TGM2
SCHEMBL324346 0.84 P2RX4 (0.47) GRIN2BALDH1A1MAOBKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 GRIN2B 1330/4885ALDH1A1 2057/4885MAOB 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.